Effect of Oral Nutritional Supplements Composed of High Protein on Body Weight Loss After Gastrectomy.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL In vivo Pub Date : 2025-01-01 DOI:10.21873/invivo.13845

Satoru Kikuchi, Nobuo Takata, Yoshihiko Kakiuchi, Shinji Kuroda, Hajime Kashima, Shunsuke Tanabe, Kazuhiro Noma, Ayako Takahashi, Shunsuke Kagawa, Toshiyoshi Fujiwara

{"title":"Effect of Oral Nutritional Supplements Composed of High Protein on Body Weight Loss After Gastrectomy.","authors":"Satoru Kikuchi, Nobuo Takata, Yoshihiko Kakiuchi, Shinji Kuroda, Hajime Kashima, Shunsuke Tanabe, Kazuhiro Noma, Ayako Takahashi, Shunsuke Kagawa, Toshiyoshi Fujiwara","doi":"10.21873/invivo.13845","DOIUrl":null,"url":null,"abstract":"Background/aim: Body weight loss (BWL) after gastrectomy for gastric cancer (GC) decreases postoperative quality of life and survival in patients with GC. This study aimed to evaluate the effect of oral nutritional supplements composed of high protein on BWL in the early period following gastrectomy.Patients and methods: Pre- and postoperative body weight and skeletal muscle mass were measured using bioelectrical impedance analysis in patients undergoing radical gastrectomy for GC and analyzed retrospectively. Patients received either a regular diet (control group, n=43) or 250 ml (320 kcal) per day of a high-protein oral nutritional supplement (ONS) (22 g protein) in addition to their regular diet (ONS group, n=40) for four weeks after gastrectomy. The actual daily intake of ONS was recorded by patients themselves. The BWL and skeletal muscle loss (SML) at one month after surgery were compared between the two groups.Results: BWL and SML at one month after surgery were similar between the two groups. In the ONS group, patients were divided into two subgroups (ONS-H and ONS-L) according to whether their ONS intake amount was above or below the average value of 216 kcal. The ONS-H group (ONS intake ≥216 kcal) showed significantly lower BWL compared to the control group (-4.6±2.6% vs. -6.2±2.5%; p=0.03). Moreover, the ONS group showed significantly lower BWL at one month after surgery than the control group in cases of total or proximal gastrectomy (-5.9±3.0% vs. -7.8±1.9%; p=0.04), although no significant difference was observed between the two groups in distal gastrectomy. The hematological nutritional parameters were similar between the two groups.Conclusion: The administration of ONS composed of high protein for four weeks after gastrectomy did not improve BWL at one month after gastrectomy. However, adequate amount of ONS intake and ONS intake after total or proximal gastrectomy might improve BWL.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"426-432"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705125/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13845","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Body weight loss (BWL) after gastrectomy for gastric cancer (GC) decreases postoperative quality of life and survival in patients with GC. This study aimed to evaluate the effect of oral nutritional supplements composed of high protein on BWL in the early period following gastrectomy.

Patients and methods: Pre- and postoperative body weight and skeletal muscle mass were measured using bioelectrical impedance analysis in patients undergoing radical gastrectomy for GC and analyzed retrospectively. Patients received either a regular diet (control group, n=43) or 250 ml (320 kcal) per day of a high-protein oral nutritional supplement (ONS) (22 g protein) in addition to their regular diet (ONS group, n=40) for four weeks after gastrectomy. The actual daily intake of ONS was recorded by patients themselves. The BWL and skeletal muscle loss (SML) at one month after surgery were compared between the two groups.

Results: BWL and SML at one month after surgery were similar between the two groups. In the ONS group, patients were divided into two subgroups (ONS-H and ONS-L) according to whether their ONS intake amount was above or below the average value of 216 kcal. The ONS-H group (ONS intake ≥216 kcal) showed significantly lower BWL compared to the control group (-4.6±2.6% vs. -6.2±2.5%; p=0.03). Moreover, the ONS group showed significantly lower BWL at one month after surgery than the control group in cases of total or proximal gastrectomy (-5.9±3.0% vs. -7.8±1.9%; p=0.04), although no significant difference was observed between the two groups in distal gastrectomy. The hematological nutritional parameters were similar between the two groups.

Conclusion: The administration of ONS composed of high protein for four weeks after gastrectomy did not improve BWL at one month after gastrectomy. However, adequate amount of ONS intake and ONS intake after total or proximal gastrectomy might improve BWL.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高蛋白口服营养补充剂对胃切除术后体重减轻的影响

背景/目的：胃癌（GC）术后体重减轻（BWL）会降低胃癌患者的术后生活质量和生存率。本研究旨在评价口服高蛋白营养补充剂对胃切除术后早期体重的影响。患者和方法：采用生物电阻抗分析法测量胃癌根治术患者术前和术后体重和骨骼肌质量，并进行回顾性分析。患者接受常规饮食（对照组，n=43）或在常规饮食（ONS组，n=40）的基础上每天服用250毫升（320大卡）的高蛋白口服营养补充剂（ONS）（22克蛋白质），持续四周。ONS的实际每日摄入量由患者自己记录。比较两组术后1个月的BWL和骨骼肌损失（SML）。结果：两组患者术后1个月BWL和SML差异无统计学意义。在ONS组中，根据ONS摄入量高于或低于216 kcal的平均值将患者分为ONS- h和ONS- l两个亚组，ONS- h组（ONS摄入量≥216 kcal）的BWL明显低于对照组(-4.6±2.6% vs -6.2±2.5%；p = 0.03)。此外，在全胃或近端胃切除术病例中，ONS组术后1个月的BWL明显低于对照组(-5.9±3.0% vs -7.8±1.9%；P =0.04)，但两组远端胃切除术无显著差异。两组患者血液学营养指标相似。结论：胃切除术后4周给予高蛋白ONS对胃切除术后1个月BWL无改善作用。然而，摄入足够量的ONS以及在全胃或近端胃切除术后摄入ONS可能会改善BWL。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.